Stockreport

Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]

Protara Therapeutics, Inc.  (TARA) 
PDF 33% at 12 months (n=15), which management attributes to small-sample volatility and expects to rise toward ~40% as the study enrolls to a planned 100 patients; the compa [Read more]